Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Suite 310, 2200 Powell Street EMERYVILLE CA 94608 |
Tel: | N/A |
Website: | https://www.xoma.com |
IR: | See website |
Key People | ||
Owen P. Hughes Chief Executive Officer, Director | Thomas Burns Chief Financial Officer, Senior Vice President - Finance | Bradley J. Sitko Chief Investment Officer |
Business Overview |
XOMA Corporation is a biotechnology royalty aggregator. The Company's royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab). |
Financial Overview |
For the fiscal year ended 31 December 2023, XOMA Corp revenues decreased 21% to $4.8M. Net loss applicable to common stockholders increased from $22.6M to $46.3M. Revenues reflect United States segment decrease of 18% to $3.7M, Asia Pacific segment decrease of 29% to $1.1M. Higher net loss reflects Stock-based Compensation in SGA increase from $3.6M to $9.1M (expense), Amortization of Intangible Assets increase from $97K to $897K (expense). |
Employees: | 13 as of Mar 4, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $242.01M as of Dec 31, 2023 |
Annual revenue (TTM): | $4.76M as of Dec 31, 2023 |
EBITDA (TTM): | -$25.12M as of Dec 31, 2023 |
Net annual income (TTM): | -$46.30M as of Dec 31, 2023 |
Free cash flow (TTM): | -$23.63M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 11,625,826 as of Mar 4, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |